Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (HYPR) expects record preliminary third-quarter 2026 revenue of approximately $6.0 million and reaffirmed its full-year revenue outlook. Revenue grew 53% from the second quarter. Expected net cash burn, excluding financing proceeds, was approximately $5.6 million, a 29% sequential improvement; quarterly revenue is expected to exceed cash burn for the first time.
For the nine months ended September 30, expected revenue was approximately $13.8 million, up 66% year over year, while expected net cash burn was approximately $22.2 million, an 8% improvement. Expected quarter-end cash and cash equivalents were approximately $37.9 million. Hyperfine continues to expect 2026 revenue of approximately $20 to $22 million and net cash burn of approximately $26 to $28 million. These imply midpoint revenue growth of 55% and a cash-burn decline of 10% versus 2025. Results are preliminary and unaudited; complete results are expected November 9, 2026.
Hyperfine (HYPR) will report third-quarter 2026 financial results on November 9, 2026, with management hosting a corresponding conference call. The call is scheduled for 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archived recording will be available through the Investors page of the company’s website.
Hyperfine (HYPR) appointed Roots Pharmaceutical its exclusive distributor for the Swoop portable brain MRI system in Kuwait and the United Arab Emirates.
Roots will support market development, local regulatory activities, product education, demonstrations and customer engagement in both countries. Commercial and service activities will follow any applicable regulatory clearances. Swoop is an FDA-cleared, AI-powered portable MRI system for brain imaging. The appointment expands Hyperfine’s global distribution network.
Hyperfine (HYPR) has completed enrollment in its Contrast PMR study evaluating contrast-enhanced use of the Swoop portable MRI system for brain imaging.
The prospective, multi-center study assesses visualization of brain lesions, including those linked to blood-brain barrier disruption, using gadolinium-based contrast agents at ultra-low field. Results are intended to support the first expansion of Swoop’s FDA-cleared indications for use, enabling contrast-enhanced brain imaging. Hyperfine plans to complete image review and data analysis and submit a 510(k) to the FDA by the end of 2026, with expanded contrast use remaining subject to clearance.
Hyperfine (Nasdaq: HYPR) announced that it will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10. Company management will host in-person investor meetings, which can be scheduled through a Lake Street representative or the company’s investor contact.
Hyperfine (Nasdaq: HYPR) reported growing adoption of its FDA-cleared, AI-powered portable brain MRI, the Swoop system, in neurology offices, highlighted by the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging and more than 3,000 in-office brain MRI scans in the first year of its office-market launch.
According to Hyperfine, NEURO PMR is the first prospective, multicenter, real-world study of portable MRI versus high-field MRI in outpatient neurology. Portable MRI showed 92% concordance with high-field MRI for structural abnormalities in blinded review, 98% with clinical information, and a four-to-one patient preference, while being deployable in standard exam rooms and used across varied neurology and brain health practices.
Hyperfine (Nasdaq: HYPR) received FDA clearance for its latest Optive AI™ software update for the Swoop® portable brain MRI system. This is the second FDA-cleared software package since the next-generation Swoop launch in mid-2025.
The new software enhances image quality across all Swoop sequences, improves proprietary noise correction in electromagnetically noisy care settings, and introduces a more guided, intuitive scanning workflow. It also debuts an isotropic T1 sequence for three-dimensional visualization and thinner slices, aimed at strengthening clinical utility in uses such as post-operative tumor follow-up. Hyperfine plans to begin rolling out the software in the United States to existing and new Swoop users in September.
Hyperfine (Nasdaq: HYPR) reported second quarter 2026 revenue of $3.9 million, up 44.8% from $2.7 million a year earlier, driven by sales of 12 Swoop® systems, a 50.0% increase. Gross profit was $2.0 million with gross margin of 50.7%, up from 49.3%.
Research and development expenses fell 14.9% to $3.9 million, while sales, marketing, general and administrative costs rose 3.2% to $6.6 million. Net loss was $9.3 million, or -$0.09 per share. Cash and cash equivalents were $43.5 million on June 30, 2026, supported by $25.3 million of first-half financing, including $13.6 million debt and $11.4 million at-the-market equity issuance.
The company obtained CE Mark and UKCA approval for the next-generation Swoop® system and Optive AI™ software, launched the next-generation Swoop® in Europe, and highlighted PRIME study data showing portable MRI reduced emergency department time to imaging. Full-year 2026 revenue guidance of $20–$22 million and cash burn guidance of $26–$28 million were reiterated.
Hyperfine (Nasdaq: HYPR) announced multiple new peer-reviewed publications supporting its FDA-cleared, AI-powered portable brain MRI, the Swoop® system, in neurosurgical and stroke care settings. New reports in the Journal of Neurosurgery describe ambulatory neurosurgery cases where Swoop imaging immediately after endovascular procedures helped confirm absence of acute ischemia or intracranial hemorrhage and enabled same-day discharge.
In addition, a Stroke journal collection reviews existing and new evidence on low-field MRI across the stroke continuum, from pre-hospital care to neurocritical care and cerebral small vessel disease, and offers implementation guidance. According to Hyperfine, Swoop is now supported by more than 180 peer-reviewed publications and editorials and over 280 scientific presentations across multiple sites of care.
Hyperfine (Nasdaq: HYPR) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026. The company, known for the first FDA-cleared AI-powered portable brain MRI, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
A live audio webcast and an archived recording will be available on the Investors page of Hyperfine’s website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the call. Additional information on the Swoop system is available at HyperfineMRI.com.